ADVM Stock Forecast 2025-2026
Distance to ADVM Price Targets
ADVM Price Momentum
🤔 Considering Adverum (ADVM)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest ADVM Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, ADVM has a bullish consensus with a median price target of $32.00 (ranging from $10.00 to $40.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $4.61, the median forecast implies a 594.1% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joon Lee at Truist Securities, projecting a 767.7% upside. Conversely, the most conservative target is provided by Luca Issi at RBC Capital, suggesting a 116.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ADVM Analyst Ratings
ADVM Price Target Range
Latest ADVM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ADVM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 19, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| Nov 5, 2024 | RBC Capital | Luca Issi | Sector Perform | Maintains | $10.00 |
| Aug 14, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $40.00 |
| Aug 13, 2024 | RBC Capital | Luca Issi | Sector Perform | Maintains | $12.00 |
| Aug 13, 2024 | HC Wainwright& Co. | Buy | Reiterates | $0.00 | |
| Aug 13, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| Jul 18, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $40.00 |
| Jun 25, 2024 | Oppenheimer | Francois Brisebois | Outperform | Initiates | $25.00 |
| May 15, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $60.00 |
| May 10, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| Apr 30, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Initiates | $30.00 |
| Apr 29, 2024 | Mizuho | Graig Suvannavejh | Buy | Maintains | $22.00 |
| Mar 19, 2024 | Chardan Capital | Daniil Gataulin | Buy | Reiterates | $4.00 |
| Mar 19, 2024 | RBC Capital | Luca Issi | Sector Perform | Maintains | $2.00 |
| Feb 6, 2024 | Mizuho | Graig Suvannavejh | Buy | Maintains | $4.00 |
| Nov 2, 2023 | Mizuho | Graig Suvannavejh | Buy | Initiates | $2.00 |
| Sep 5, 2023 | Truist Securities | Joon Lee | Buy | Reiterates | $6.00 |
| Aug 11, 2023 | Chardan Capital | Buy | Upgrade | $0.00 | |
| Mar 7, 2023 | Ladenburg Thalmann | Aydin Huseynov | Buy | Initiates | $2.00 |
| Nov 11, 2022 | Chardan Capital | Daniil Gataulin | Neutral | Maintains | $2.00 |
Adverum Biotechnologies, Inc. (ADVM) Competitors
The following stocks are similar to Adverum based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Adverum Biotechnologies, Inc. (ADVM) Financial Data
Adverum Biotechnologies, Inc. has a market capitalization of $96.32M with a P/E ratio of -0.4x. The company generates $1.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -2,922.1% and return on equity of -76.3%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Adverum Biotechnologies, Inc. (ADVM) Business Model
About Adverum Biotechnologies, Inc.
Develops gene therapies for ocular and rare diseases.
The company focuses on creating durable, single-administration gene therapies aimed at treating serious ocular conditions. By utilizing its innovative vector platform for therapeutic gene delivery, Adverum generates revenue through the development and commercialization of its product candidates, primarily targeting retinal diseases.
Adverum collaborates with research institutions and industry experts to enhance its gene therapy initiatives. Based in Redwood City, California, the company is positioned at the forefront of biotechnology and healthcare, with a mission to address unmet medical needs and significantly impact patient care and regenerative medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
121
CEO
Dr. Laurent Fischer
Country
United States
IPO Year
2014
Website
adverum.comAdverum Biotechnologies, Inc. (ADVM) Latest News & Analysis
Adverum Biotechnologies has launched the ARTEMIS Phase 3 trial to assess Ixo-vec's safety and efficacy as a single IVT injection for wet age-related macular degeneration.
The initiation of the ARTEMIS Phase 3 study for Ixo-vec could significantly impact Adverum’s stock, as successful outcomes may lead to regulatory approval and increased market value in gene therapy.
Adverum Biotechnologies granted inducement awards of stock options for 44,380 shares and RSUs for 22,790 shares to 5 new employees, per Nasdaq regulations.
The issuance of stock options and RSUs can signal potential growth and talent acquisition, impacting stock value and indicating management's commitment to fostering new talent.
Adverum Biotechnologies will present at the Cowen 45th Annual Healthcare Life Sciences Conference on March 4 at 11:50 a.m. ET, focusing on gene therapy for ocular diseases.
Adverum Biotechnologies' conference presentation may signal advancements in gene therapy, influencing investor sentiment and stock performance in the biotech sector.
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
1 month agoAdverum Biotechnologies, Inc. (Nasdaq: ADVM) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11 at 4:40 p.m. ET, focusing on gene therapy for ocular diseases.
Adverum Biotechnologies' presentation at a major healthcare conference could indicate progress in gene therapy for ocular diseases, potentially impacting stock value and investor sentiment.
Adverum Biotechnologies granted 55,000 non-qualified stock options to a new employee on November 17, 2024, under its 2017 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4).
The grant of stock options indicates confidence in new talent and potential future performance, which can positively influence stock value and investor sentiment.
Adverum Biotechnologies reported positive results from LUNA and OPTIC studies on Ixo-vec for wet age-related macular degeneration. The phase 3 ARTEMIS study is set to start in H1 2025.
Positive trial results for Adverum's Ixo-vec in treating wet AMD boost its market potential in a lucrative $19.53 billion sector, signaling growth opportunities for investors.
Frequently Asked Questions About ADVM Stock
What is Adverum Biotechnologies, Inc.'s (ADVM) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Adverum Biotechnologies, Inc. (ADVM) has a median price target of $32.00. The highest price target is $40.00 and the lowest is $10.00.
Is ADVM stock a good investment in 2025?
According to current analyst ratings, ADVM has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.61. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ADVM stock?
Wall Street analysts predict ADVM stock could reach $32.00 in the next 12 months. This represents a 594.1% increase from the current price of $4.61. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Adverum Biotechnologies, Inc.'s business model?
The company focuses on creating durable, single-administration gene therapies aimed at treating serious ocular conditions. By utilizing its innovative vector platform for therapeutic gene delivery, Adverum generates revenue through the development and commercialization of its product candidates, primarily targeting retinal diseases.
What is the highest forecasted price for ADVM Adverum Biotechnologies, Inc.?
The highest price target for ADVM is $40.00 from Joon Lee at Truist Securities, which represents a 767.7% increase from the current price of $4.61.
What is the lowest forecasted price for ADVM Adverum Biotechnologies, Inc.?
The lowest price target for ADVM is $10.00 from Luca Issi at RBC Capital, which represents a 116.9% increase from the current price of $4.61.
What is the overall ADVM consensus from analysts for Adverum Biotechnologies, Inc.?
The overall analyst consensus for ADVM is bullish. Out of 13 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $32.00.
How accurate are ADVM stock price projections?
Stock price projections, including those for Adverum Biotechnologies, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
